JPRN-UMIN000013247已完成2 期
A phase II feasibility study of surgical intervention for single station cN2 (UICC 6) non-small cell lung cancer (JNETS 0801) - Feasibility study of surgery for single station cN2
Japan North-East Area Thoracic Oncology Study Group0 个研究点目标入组 34 人开始时间: 2014年2月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Mediastinal lymphnodes with above 20mm in their shorter diameter. cN2 with over 2 stations. General contraindication for the thoracotomy with low cardio-pulmonary function, liver or renal dysfunction and the others. Age over 76. Extra-nodal invation of cN2 nodes. Distant metastasis. Other malignancies. #1-3(UICC 6) lymphnodes swelling in left side mediastinum. preceding hemotherapy, molecular targetting therapy, thoracic radiotherapy
研究者
相似试验
招募中
2 期
Phase II clinical trial of surgical intervention following chemotherapy for synchronous and metachronous liver metastasis from gastric cancer.Patients with synchronous or metachronous liver metastasis from gastric cancerJPRN-UMIN000011445Department of Surgery, Osaka University Graduate School of Medicine50
招募中
2 期
Phase II clinical trial of surgical intervention following chemotherapy for synchronous and metachronous liver metastasis from gastric cancer.(HiSCO 06)Patients with synchronous or metachronous liver metastasis from gastric cancerJPRN-UMIN000024004Hiroshima Surgical Study group of Clinical Oncology (HiSCO)30
已完成
2 期
Phase2 study of limited Surgery for T1 or T2 lower rectal Cancer with adjuvant chemoradiotherapyRectal cancerJPRN-UMIN000007184Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group50
招募中
2 期
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBNon Small Cell Lung CancerNCT05295212Hunan Province Tumor Hospital120
进行中（未招募）
1 期
Clinical study to assess the safety and preliminary efficacy of HCR040, a drug based on mesenchymal stem cells, in patients with acute respiratory distress syndrome. (included patients COVID-19)acute respiratory distress syndromeEUCTR2019-002688-89-ESHistocell S.L.26